Georgia's Online Cancer Information Center

Find A Treatment Site

Piedmont Cancer Institute - Stockbridge

Piedmont Cancer Institute, PC (formerly Peachtree Hematology-Oncology Consultants, PC) physicians are specialists in the treatment and prevention of cancer and blood disorders. The treatment philosophy includes the approach that during the healthcare experience at Piedmont Cancer Institute, PC, physicians are partners with the patient. The practice provides patients and their families with the most current medical knowledge and treatment available; education about your specific treatment; psychological and emotional support; access to community resources and support groups; and access to clinical trials and research protocols. The center is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers.

Treatment Sites in Georgia

Primary Location

1240 Eagles Landing Parkway
Suite 260
Stockbridge, GA 30281
678-854-9500 (p)
678-854-9502 (f)
www.piedmontcancerinstitute.com

driving directions

Clinical Trials in Georgia

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
Cancer Type: Prostate Cancer , Unknown Primary

A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Cancer Type: Breast Cancer, Esophogeal Cancer, Head and Neck Cancer, Stomach/ Gastric Cancer

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Cancer Type: Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer , Solid Tumor, Stomach/ Gastric Cancer, Unknown Primary, Uterine Cancer

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
Cancer Type: Pancreatic Cancer

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
Cancer Type: Lung Cancer, Neuroendocrine Tumor, Unknown Primary

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Cancer Type: Breast Cancer, Unknown Primary

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Cancer Type: Bile Duct Cancer

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Cancer Type: Breast Cancer

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Cancer Type: Prostate Cancer
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.